How cutting off tumors' blood supply is reshaping cancer and eye disease treatment

A major review of angiogenesis-blocking drugs reveals how starving cancers of new blood vessels has become a linchpin strategy across oncology and ophthalmology. The findings matter to pharmaceutical companies, hospital systems, and policymakers investing in these therapies—which now represent a multi-billion-dollar market segment with expanding applications beyond traditional indications.

Originaltitel: Targeting angiogenesis in oncology, ophthalmology and beyond